Cancer Library VCC

The only cancer specialist library service in Wales. Supporting NHS and academic staff, students and health professionals throughout the Principality.

[Cancer Library VCC @VCCLibrary]

🎶Oh the weather outside is frightful, but the @immunobuddies are so delightful...🎶 Episode 226: When Immunotherapy Meets A Transplanted Organ. @VelindreCS @RickyFrazer1 @AOlssonBrown https://t.co/DEUirjjzcx

[Cancer Library VCC @VCCLibrary]

Rilvegostomig Plus Trastuzumab-Deruxtecan for Early-Stage #BreastCancer: The I-SPY2.2 Randomized Clinical Trial. https://t.co/AvEJYcg2fa

[Cancer Library VCC @VCCLibrary]

The ESMO Scale for Clinical Actionability of Molecular Targets, version 2 (ESCAT v2): an evidence-based framework for ranking alterations as actionability and resistance biomarkers in precision oncology. https://t.co/uKYniSn3uF

[Cancer Library VCC @VCCLibrary]

Gastric and oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. https://t.co/MVE6E2oyUf

[Cancer Library VCC @VCCLibrary]

Efficacy and safety of camrelizumab plus docetaxel and carboplatin as neoadjuvant therapy for stage II-III triple-negative #BreastCancer: the HELEN-Trio 011 randomized clinical trial. https://t.co/nn9mKEqhFM

[Cancer Library VCC @VCCLibrary]

Nivolumab + relatlimab with platinum-doublet chemotherapy vs nivolumab with platinum-doublet chemotherapy in stage IV or recurrent non-small cell #LungCancer: clinical, translational, and patient-reported outcomes results- phase II RELATIVITY-104 study. https://t.co/6RxNcQ57T1

[Cancer Library VCC @VCCLibrary]

Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient #ColonCancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial. https://t.co/VpWrVbPNvE

[Cancer Library VCC @VCCLibrary]

Clinical implications of germline and somatic genetic testing in ovarian carcinoma: BRCA and beyond. The PERSONA-Ovary trial. https://t.co/D96fod18Cl

[Cancer Library VCC @VCCLibrary]

Phase I and early phase II study of enhancing immune checkpoint inhibitor efficacy using a Mycobacterium tuberculosis extract combined with radiation therapy in non-small cell #LungCancer patients: NEJ046A. https://t.co/gbjCzTfqaN

[Cancer Library VCC @VCCLibrary]

Feasibility of Real-Time Integration of a Large Language Model in the EHR to Identify Goals-of-Care Documentation. https://t.co/MdxTSOiSGb

[Cancer Library VCC @VCCLibrary]

US-based Delphi Consensus Study on Adjuvant Radiation Therapy (ART) in Node-Negative Cutaneous Squamous Cell Carcinoma (CSCC). https://t.co/bKu89YnDyQ

[Cancer Library VCC @VCCLibrary]

Organ Preservation With Total Neoadjuvant Therapy (OPTNT) for Early Low #RectalCancer: Short-Term Outcomes of a Nonrandomized Phase 2 Clinical Trial. https://t.co/dC0puY9z8E

[Cancer Library VCC @VCCLibrary]

How to plan and deliver #LungCancer reirradiation: A consensus approach from the ESTRO reirradiation and lung focus groups and ReCOG. https://t.co/nAER5ir4Dp

[Cancer Library VCC @VCCLibrary]

Harmonizing spatially fractionated radiation therapy: consensus and roadmap from an ESTRO workshop. https://t.co/QnJlim5ABK

[Cancer Library VCC @VCCLibrary]

Carbon ion radiotherapy for non-metastatic #PancreaticCancer: final results of the prospective phase 2 PACK-study (NCT04194268). https://t.co/oXGu86UVUl

[Cancer Library VCC @VCCLibrary]

Cardiovascular Toxicity Across the #Cancer Immunotherapy Spectrum: Mechanisms and Management in Immune Checkpoint Inhibitor (ICI) and Chimeric Antigen Receptor T-Cell (CAR-T) Therapy. @RickyFrazer1 @VelindreCS https://t.co/YK81g3wh8H

[Cancer Library VCC @VCCLibrary]

NICE Technology Appraisal Guideline [TA1202]: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic #BreastCancer after 1 or more lines of anti-HER2 treatment. @NICEComms https://t.co/XUK7sJ8hWw

[Cancer Library VCC @VCCLibrary]

Impact of remote management using patient-reported outcomes on pain and anxiety after breast biopsy: the BIO-PSY randomized controlled trial. https://t.co/ZyN0L2ohq9

[Cancer Library VCC @VCCLibrary]

Bolus-only versus bolus plus continuous infusion hydromorphone for refractory #Cancer pain: a prospective, multicenter, randomized noninferiority trial. https://t.co/YbhuwYncUM

[Cancer Library VCC @VCCLibrary]

Cobimetinib + Vemurafenib in Patients With BRAF V600E–Mutant Papillary Thyroid and Biliary Tract #Cancers: Results From the TAPUR Study. https://t.co/v9x3HRbcOt